Format

Send to

Choose Destination
Food Chem Toxicol. 2014 Aug;70:61-7. doi: 10.1016/j.fct.2014.04.040. Epub 2014 May 6.

Evaluation of the toxicological safety of erinacine A-enriched Hericium erinaceus in a 28-day oral feeding study in Sprague-Dawley rats.

Author information

1
Grape King Biotechnology Inc., Zhong-Li 320, Taiwan. Electronic address: ichen.li@grapeking.com.tw.
2
Grape King Biotechnology Inc., Zhong-Li 320, Taiwan. Electronic address: lan.chen@grapeking.com.tw.
3
Grape King Biotechnology Inc., Zhong-Li 320, Taiwan. Electronic address: ly.lee@grapeking.com.tw.
4
Grape King Biotechnology Inc., Zhong-Li 320, Taiwan. Electronic address: wp.chen@grapeking.com.tw.
5
Testing Center, Super Laboratory Inc., Taipei 24890, Taiwan. Electronic address: r91445202@gmail.com.
6
Grape King Biotechnology Inc., Zhong-Li 320, Taiwan. Electronic address: gkbioeng@grapeking.com.tw.
7
Department of Food Science and Biotechnology, National Chung Hsing University, Taichung 402, Taiwan. Electronic address: cschen@mail.nchu.edu.tw.

Abstract

Natural products have attained great importance as they are believed to be the new alternative medicines for conventional therapy. As numerous studies have proved the tremendous medicinal values of Hericium erinaceus, it is necessary to take into account its safety as well as its risk for the recipient. However, mushroom mycelium has an identity distinct from mushrooms, as two specific classes of compounds, hericenones and erinacines, can only be extracted from both the fruit body and the cultured mycelium, respectively. Therefore, this is the first report on the evaluation of the toxicity of H.erinaceus mycelium, enriched with 5mg/g erinacine A, by a 28-day repeated oral administration study in Sprague-Dawley rats. Three doses of 1 (Low), 2 (Mid) and 3 (High) g/kg body weight/day were selected for the study while distilled water served as control. All animals survived to the end of the study. No abnormal changes were observed in clinical signs. No adverse or test article-related differences were found in urinalysis, haematology and serum biochemistry parameters, between the treatment and control groups. No gross pathological findings and histopathological differences were seen. Therefore, the no-observed-adverse-effect level of erinacine A-enriched H.erinaceus is greater than 3g/kgbody weight/day.

KEYWORDS:

Erinacine A; Hericium erinaceus; Safety assessment; Sub-acute toxicity

PMID:
24810469
DOI:
10.1016/j.fct.2014.04.040
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center